Latest | Instant Finance & Market News_第73页 | NewTimeSpace

09:02

[ LAM SOON (HK)(00411.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at HKD 293.37 million, YoY decrease of 3.16% ] NewTimeSpace News: September 07, 2026, LAM SOON (HK)(00411.HK) released its Annual Report for the period ended June 30, 2026, Total Revenue stood at HKD 5.06 billion, increased by 4.84% YoY.

Tag： LAM SOON (HK)00411.HK Profit declined

07:52

[ FIBOCOM (00638.HK): Closes Sale of Entire Stake in Shanghai Guangyi to Luxshare Precision; De-consolidated from 4 September ] On 7 September 2026, FIBOCOM (00638.HK) announced the closing of the sale of its aggregate 100% stake in Shanghai Guangyi to Luxshare Precision on 4 September 2026. Post-closing, Shanghai Guangyi is de-consolidated from the company's reporting scope; the company said the transaction is expected to optimize its current-year operating performance and supports its focus on core businesses.

Tag： FIBOCOM 00638.HK Equity Disposal

07:44

[ DEEP SOURCE (00990.HK): Malaysia AIDC Project Approved by MITI, Entering Accelerated Deployment Phase ] On 7 September 2026, DEEP SOURCE (00990.HK) announced that its AI data center (AIDC) project in Malaysia has been approved by MITI, with certain water and electricity conditions being implemented.

Tag： DEEP SOURCE 00990.HK Business Update

07:42

[ POLY XVERSE IT (00209.HK): Chairman and Executive Director Zhao Kai Resigns, Effective 7 September 2026 ] On 7 September 2026, POLY XVERSE IT (00209.HK) announced that Chairman and Executive Director Zhao Kai has resigned, effective 7 September 2026, to focus on other business arrangements, confirming no disagreement with the Board and no matters requiring shareholder or exchange attention.

Tag： POLY XVERSE IT 00209.HK

07:37

[ BIOHEART-B (02185.HK): Appoints Former Medtronic and ReCor Medical Executive Giorgio Gobbi as VP of Global Therapy Development at AngioCare ] On 7 September 2026, BIOHEART-B (02185.HK) announced that Giorgio Gobbi, formerly a senior executive at Medtronic and ReCor Medical, has joined subsidiary AngioCare as VP of Global Therapy Development, leading global development of the Iberis® RDN system.

Tag： BIOHEART-B 02185.HK

07:34

[ UISEE TECH (01511.HK): Shares Added to Stock Connect Eligible Securities List, Effective 7 September 2026 ] On 8 September 2026, UISEE TECH (01511.HK) announced that its shares have been added to the Stock Connect eligible securities list, effective 7 September 2026, enabling qualified mainland investors to trade through the Stock Connect channel. The company said the inclusion will help broaden its shareholder base and enhance liquidity, as it deepens its global presence in full-scenario L4 autonomous driving.

Tag： UISEE TECH 01511.HK Stock Connect

07:29

[ MAJESTIC DRAGON (00918.HK): Appoints Zhang Chen as Chief Marketing Officer, Effective 7 December 2026 ] On 7 September 2026, MAJESTIC DRAGON (00918.HK) announced the appointment of Mr. Zhang Chen as Chief Marketing Officer, effective 7 December 2026.

Tag： MAJESTIC DRAGON 00918.HK Executive Appointment

22:42

[ KINWONG (603228.SH): passes listing hearing on HKEX; the world's largest automotive electronics PCB supplier set for Hong Kong listing ] On 7 September 2026, KINWONG (603228.SH) passed the listing hearing on HKEX, with CITIC Securities, BofA Securities and Guolian Securities International as joint sponsors. According to CIC, the company was the world's largest automotive electronics PCB supplier by 2025 revenue (market share of 10.6%) and ranked eleventh globally among PCB suppliers (2.5%), with products covering automotive electronics, communications and data infrastructure, smart devices and industrial control, and mass production of high-end PCBs for AI computing infrastructure such as high-multilayer PCBs with more than 40 layers.

Tag： KINWONG 603228.SH IPO A+H pass the listing hearing

22:31

[ JIU RONG HOLD (02358.HK): Subsidiary Zhejiang Jiurong Intelligence faces lease dispute lawsuit over about RMB 17.06 million in unpaid rent ] On 7 September 2026, JIU RONG HOLD (02358.HK) announced that its indirect wholly-owned subsidiary Zhejiang Jiurong Intelligence had received a notice of response from the Qiantang District People's Court of Hangzhou in a housing lease dispute filed by Shuyuan Technology Innovation Development, seeking outstanding rent of RMB 17,056,660.8 plus litigation costs and preservation fees under five lease contracts signed between 2022 and 2025 (with total rent of RMB 17,606,660.8). The hearing is scheduled for 22 October 2026, and the company said the lawsuit may exert pressure on its cash flow and working capital and that it will actively respond while pursuing settlement discussions with creditors.

Tag： JIU RONG HOLD 02358.HK Litigation

22:28

[ LONGSYS (09976.HK): H-share global offering 40.32 times subscribed under Hong Kong public offering, listing on 8 September with net proceeds of about HKD 6.80 billion ] On 7 September 2026, LONGSYS (09976.HK) published the allotment results for its H-share global offering: the final offer price is HKD 236.00 per share, with trading to commence on 8 September; the Hong Kong public offering was 40.32 times subscribed (36,285 valid applications) and the international offering 3.88 times subscribed (227 placees). The global offering comprised 29,989,450 shares, including 3,911,650 additional shares issued under the offer size adjustment right, generating gross proceeds of approximately HKD 7,077.5 million and net proceeds of approximately HKD 6,803.2 million.

Tag： LONGSYS 09976.HK Listing IPO

22:26

[ MICOT PHARMA-B (02335.HK): H shares included in eligible list under Stock Connect ] On 7 September 2026, MICOT PHARMA-B (02335.HK) voluntarily announced that its H shares had been included in the eligible share list under the Stock Connect schemes (Shanghai-Hong Kong and Shenzhen-Hong Kong), effective from the same day, pursuant to the announcements of the two exchanges. Eligible mainland investors will be able to trade the company's shares through the two exchanges.

Tag： Micot Pharma-B 02335.HK Stock Connect

22:23

[ LONGBIO-B (01779.HK): Shares included in eligible securities list under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect ] On 7 September 2026, LONGBIO-B (01779.HK) voluntarily announced that it had been included in the eligible securities lists under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect schemes, effective from the same day, pursuant to the notices issued by the Shanghai and Shenzhen stock exchanges. Eligible mainland investors will be able to trade the company's shares directly through the two exchanges, and the company expects the inclusion to broaden its shareholder base and improve share liquidity.

Tag： LongBio-B Stock Connect 01779.HK

22:06

[ LONGFOR GROUP (00960.HK): Contracted sales of RMB 2.20 billion in August 2026, cumulative RMB 20.84 billion in the first eight months ] On 7 September 2026, LONGFOR GROUP (00960.HK) announced its unaudited operational data for August 2026: contracted sales of RMB 2.20 billion with contracted sales area of 250,000 sq.m. in the month (RMB 1.50 billion attributable to shareholders' interests), and cumulative total contracted sales of RMB 20.84 billion with contracted sales area of 2,239,000 sq.m. for the eight months ended 31 August 2026, together with operations and services revenue (exclusive of tax) of approximately RMB 18.18 billion over the same period.

Tag： LONGFOR GROUP 00960.HK Business Data

22:02

[ ESTUN (02715.HK): Completion of acquisition of 100% equity in Estun Kuzhuo for RMB 487.1 million ] On 7 September 2026, ESTUN (02715.HK) announced the completion of its acquisition of 100% equity in Estun Kuzhuo on 2 September 2026 in accordance with the acquisition agreement, making it an indirect wholly-owned subsidiary consolidated into the group's financial statements. The cash acquisition, with a total consideration of RMB 487.10 million, was approved by the board and the extraordinary shareholders' meeting and constitutes a connected transaction.

Tag： ESTUN 02715.HK acquisition

21:58

[ MINIEYE (02431.HK): Chairman and general manager Liu Guoqing increases H-share holdings by 100,000 shares ] On 7 September 2026, MINIEYE (02431.HK) voluntarily announced that chairman, executive director and general manager Dr. Liu Guoqing had purchased 100,000 H shares on the open market at an average price of approximately HKD 2.3835 per share, representing approximately 0.02% of the issued shares. Following the purchase, his beneficial holdings increased to 34,583,503 shares (approximately 7.8%), with aggregate holdings of approximately 17.55% together with his concert parties.

Tag： MINIEYE 02431.HK Share Increase

21:49

[ CICC (03908.HK): CSRC approves merger with Dongxing Securities and Cinda Securities; H-share cash election period set for 15-17 September ] On 7 September 2026, CICC (03908.HK) announced that the CSRC had issued an approval (Zhengjian Xuke [2026] No. 2377) approving and consenting to the registration of its merger by absorption of Dongxing Securities and Cinda Securities together with related shareholding changes, satisfying the CSRC approval condition for the merger agreement. The company also set out its cash election arrangements: with the 2025 final dividend paid, the cash prices have been adjusted to RMB 34.57 per A share and HKD 18.60 per H share, and the H-share election period runs from 15 to 17 September (closing 4:30 p.m. on 17 September). CICC H shares closed at HKD 21.90 on 4 September, a premium of about 17.74% over the exercise price, and exercising the election may result in losses.

Tag： CICC 03908.HK Mergers and Acquisitions

21:37

[ VIVA GOODS (00933.HK): Further acquisition of 19,231,000 shares in Li Ning, raising stake to 19.04% ] On 7 September 2026, VIVA GOODS (00933.HK) announced that its wholly-owned subsidiary had further acquired 19,231,000 shares in Li Ning (02331.HK) on the open market through the Stock Exchange for a total consideration of approximately HKD 263,736,000 (approximately HKD 13.71 per share), raising its stake from approximately 18.30% to 19.04%. As two applicable percentage ratios exceed 5% but remain below 25%, the acquisition constitutes a discloseable transaction, while the company's two earlier rounds of acquisitions were each classified as major transactions.

Tag： VIVA GOODS 00933.HK LI NING 02331.HK acquisition

21:32

[ UNITED LAB (03933.HK): UBT251 injection completes first participant dosing in Phase III clinical study for type 2 diabetes in China ] On 7 September 2026, UNITED LAB (03933.HK) voluntarily announced that UBT251 injection, a Class 1 innovative drug developed by its wholly-owned subsidiary United Bio-Tech, had completed first participant dosing in the Phase III clinical study for type 2 diabetes in China, which comprises UNIGUIDE-1 (360 participants, placebo-controlled) and UNIGUIDE-2 (956 participants, semaglutide-controlled). UBT251 is a long-acting GLP-1/GIP/GCG triple receptor agonist; the company is the first in China and the second globally to obtain clinical approval for such an agonist prepared by chemical synthesis of peptides, and entered into an exclusive license agreement with Novo Nordisk in March 2025.

Tag： UNITED LAB 03933.HK R&D Progress

21:27

[ LDROBOT (01236.HK): Shares included in the Stock Connect eligible securities list under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect ] On 7 September 2026, LDROBOT (01236.HK) voluntarily announced that its shares had been included in the eligible securities lists of Stock Connect under both the Shanghai-Hong Kong and Shenzhen-Hong Kong schemes, effective from the same day, following the notices issued by the two exchanges. The company believes the inclusion will enhance its capital market recognition, broaden its shareholder base and improve share liquidity.

Tag： LDROBOT 01236.HK Stock Connect

21:23

[ OCT (ASIA) (03366.HK): Plans open listing sale of 100% equity in OCT (Changshu) Investment, potential disposal expected to constitute a major transaction ] On 7 September 2026, OCT (ASIA) (03366.HK) announced that it plans to dispose of the entire equity interest in OCT (Changshu) Investment, an indirect wholly-owned subsidiary engaged in industrial park operation and leasing, through an open listing process on the Beijing Equity Exchange, with the potential disposal expected to constitute a major transaction under Chapter 14 of the Listing Rules if materialized. The target recorded revenue of RMB 3.24 million and net profit of RMB 0.37 million in H1 2026, with total assets of RMB 80.81 million and total liabilities of RMB 6.96 million as of 30 June 2026. The disposal is at the preliminary information disclosure stage, subject to conditions precedent including shareholders' approval, and is independent of the potential disposal of OCT (Changshu) Industrial Development announced on the same date.

Tag： OCT (ASIA)03366.HK Asset Disposal

Scan QR Code

Download App